Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1038 results
April 2015
-
Media ReleaseNovartis celebrates 19th annual Community Partnership Day with more than 27,000 associates volunteering in their local communitiesMore than 27,000 Novartis associates worldwide dedicate an estimated 200,000 hours to volunteer with charitable causes in their communities Community Partnership Day symbolizes the company'…
-
Media ReleaseData at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patientsNew FREEDOMS/FREEDOMS II sub-group analysis showed Gilenya-treated patients were six-times more likely to achieve 'no evidence of disease activity (NEDA4)' vs placebo NEDA4 is based on four…
-
Media ReleaseSandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mgGlatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Novartis and Sandoz are driving access to a full…
-
Media ReleaseAlcon receives FDA approval of new multifocal intraocular lens to treat cataract patients in the United StatesUS Food and Drug Administration (FDA) grants approval of the AcrySof® IQ ReSTOR® +2.5 Diopter (D) Intraocular Lens (IOL) for sale in the US Expands Alcon's IOL portfolio for the …
-
Media ReleaseData in The Lancet show Novartis drug Arzerra® plus chlorambucil improved median progression-free survival by 71% in CLL patientsSignificant improvement in PFS seen with Arzerra plus chlorambucil in previously untreated patients with CLL for whom fludarabine-based therapy was inappropriate Chronic lymphocytic…
-
Media ReleaseGilenya® data at AAN to highlight Novartis leadership in innovation with new MS assessment methods to benefit patients and physiciansNew analysis will confirm high efficacy of Gilenya® in achieving 'no evidence of disease activity' (NEDA4) in previously-treated highly-active RMS patients Separate analyses will show adding…
March 2015
-
Media ReleaseNovartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overloadJadenu (deferasirox), a new formulation of Exjade (deferasirox), is the only once-daily oral tablet for iron chelation Jadenu, taken with or without food, simplifies daily treatment…
-
Media ReleaseNovartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research groupCollaboration with Aduro is focused on discovery and development of next generation cancer immunotherapies targeting the STING signaling pathway Addition of STING agonists further enhances…
-
Media ReleaseNovartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in psoriasis patientsAfter two full years of therapy with Cosentyx 300 mg, almost 9 out of 10 psoriasis patients sustained their PASI 75 response[1] New data at AAD shows 7 out of 10 psoriasis patients, who…
-
Media ReleaseNew Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patientsCLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx(TM) compared to Stelara® at Week 16[1] Cosentyx showed greater improvements…
-
Media ReleaseNovartis receives EU approval for Jakavi® in polycythemia vera, first targeted therapy approved for patients with this rare blood cancerJakavi® (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea PV is a rare blood cancer associated with…
-
Media ReleaseNovartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient benefit in achieving clear skinDetailed results from the CLEAR study will be revealed showing Cosentyx superiority to Stelara® in clearing skin (PASI 90 and PASI 100)[1] New data from the long-term Phase III program to…
Pagination
- ‹ Previous page
- 1
- …
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- › Next page